A recent phase III clinical trial (FLAURA) demonstrated that in patients with EGFR-mutated NSCLC, progression-free survival (PFS) was longer for those treated with first-line osimertinib than for those treated with gefitinib or erlotinib13. This evidence concerns the gene EGFR and non-small cell lung carcinoma.